Market
Regulatory approval for hypothalamus stimulation for spinal cord injuries in Switzerland by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcement from Swissmedic or other relevant Swiss regulatory body
Story
Swiss Researchers Use Hypothalamus Stimulation and Implants to Restore Walking in Paralysed Patients
Dec 2, 2024, 07:03 PM
Swiss researchers have achieved a breakthrough in spinal cord injury rehabilitation by using deep brain stimulation (DBS) targeting the lateral hypothalamus. The study, published in Nature Medicine and conducted by researchers from EPFL and Lausanne University Hospital, enabled two partially paralysed patients to regain the ability to walk short distances and climb stairs. This pioneering technique, involving electrode implants, activates residual neural connections, promoting recovery of lower limb movements. The findings were validated in preclinical models involving mice and rats, as well as in a first-in-human feasibility study. The research highlights the potential of DBS as a transformative therapy for spinal cord injuries.
View original story
Similar markets
Yes • 50%
No • 50%
No • 50%
Yes • 50%
European Union • 25%
Other • 25%
United States • 25%
China • 25%
No • 50%
Yes • 50%
European Union • 25%
Other • 25%
Switzerland • 25%
United States • 25%
Widespread clinical trials • 25%
None of the above • 25%
Full mobility restoration in a patient • 25%
FDA approval • 25%
Mayo Clinic • 25%
Johns Hopkins Hospital • 25%
Other • 25%
Cleveland Clinic • 25%
No • 50%
Yes • 50%
